ALKERMES | ALKS - Equity Capital And Reserves



ALKERMES reported $1.62B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
ALKERMES USD 1.62B 113M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
J&J USD 78.11B 6.62B Mar/2025
Malin Corporation EUR 193.2M 75M Dec/2024
Merck USD 49.06B 725M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Otsuka Holdings JPY 2.72T 74.2B Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025